Clinical Trial

A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an open-label, randomized, crossover study to evaluate the relative bioavailability (rBA) and bioequivalence (BE) of a test capsule formulation of varegacestat compared to reference capsules formulation under fasting conditions.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-20.
Trial Details
NCT Number NCT07610005
Lead Sponsor Immunome, Inc.
Conditions Healthy
Enrollment 20 participants
Start Date 2026-05-21
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2026-06-08